Stock FENC FENNEC PHARMACEUTICALS INC.
Add to a list
To use this feature you must be a member
Log inSign up

Other languages Fennec Pharmaceuticals Inc.

Equities

FENC

CA31447P1009

Market Closed - Nasdaq
Other stock markets
 21:00:00 26/04/2024 BST 		5-day change 1st Jan Change
9.21 USD +0.55% Intraday chart for Fennec Pharmaceuticals Inc. -1.39% -17.91%
04-23 Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing MT
04-19 Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing MT

Other languages

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Fennec Pharmaceuticals Insider Sold Shares Worth $414,472, According to a Recent SEC Filing
Fennec Pharmaceuticals Insider Sold Shares Worth $433,996, According to a Recent SEC Filing
Fennec Pharmaceuticals Insider Sold Shares Worth $457,182, According to a Recent SEC Filing
Fennec Pharmaceuticals Insider Sold Shares Worth $958,669, According to a Recent SEC Filing
Fennec Pharmaceuticals Insider Sold Shares Worth $437,451, According to a Recent SEC Filing
Fennec Pharmaceuticals up 3.2% in US Premarket, Reports Narrower Q4 Loss of $0.10 Per Share
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Sector Update: Health Care Stocks Steady Premarket Monday
Sector Update: Health Care
Fennec Pharmaceuticals Inc. and Norgine Enter into Exclusive Licensing Agreement to Commercialize PEDMARQSI in Europe, Australia, and New Zealand
Fennec Pharmaceuticals Inc. Provides Unaudited Earnings Guidance for the Fourth Quarter and Full Year of 2023
Wedbush Reviews Fennec Pharmaceuticals' Q3 Results
Fennec Pharmaceuticals Reports Pedmark Net Product Revenue of US$6.5 Million In Q3 2023
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2023
Wedbush Reviews Fennec Pharmaceuticals' Q2
Fennec Pharmaceuticals Reports Q2 2023 Net Loss of US$5.4 Million; Appoints Adrian Haigh as Chief Operating Officer
Fennec Pharmaceuticals Inc. Reports Earnings Results for the Second Quarter Ended June 30, 2023
Fennec Pharmaceuticals Inc. Announces the Appointment of Adrian Haigh as Chief Operating Officer
Insider Sell: Fennec Pharmaceuticals
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. FENC Stock
  4. News Fennec Pharmaceuticals Inc.
  5. Other languages